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Abstract
Background: The administration of sedatives in terminally ill patients becomes an increasingly
feasible medical option in end-of-life care. However, sedation for intractable distress has raised
considerable medical and ethical concerns. In our study we provide a critical analysis of seven years
experience with the application of sedation in the final phase of life in our palliative care unit.
Methods: Medical records of 548 patients, who died in the Palliative Care Unit of GK Havelhoehe
between 1995–2002, were retrospectively analysed with regard to sedation in the last 48 hrs of
life. The parameters of investigation included indication, choice and kind of sedation, prevalence of
intolerable symptoms, patients' requests for sedation, state of consciousness and communication
abilities during sedation. Critical evaluation included a comparison of the period between 1995–
1999 and 2000–2002.
Results: 14.6% (n = 80) of the patients in palliative care had sedation given by the intravenous
route in the last 48 hrs of their life according to internal guidelines. The annual frequency to apply
sedation increased continuously from 7% in 1995 to 19% in 2002. Main indications shifted from
refractory control of physical symptoms (dyspnoea, gastrointestinal, pain, bleeding and agitated
delirium) to more psychological distress (panic-stricken fear, severe depression, refractory
insomnia and other forms of affective decompensation). Patients' and relatives' requests for
sedation in the final phase were significantly more frequent during the period 2000–2002.
Conclusion:  Sedation in the terminal or final phase of life plays an increasing role in the
management of intractable physical and psychological distress. Ethical concerns are raised by
patients' requests and needs on the one hand, and the physicians' self-understanding on the other
hand. Hence, ethically acceptable criteria and guidelines for the decision making are needed with
special regard to the nature of refractory and intolerable symptoms, patients' informed consent and
personal needs, the goals and aims of medical sedation in end-of-life care.
Background
Sedation in the final stage of life is a controversial issue in
palliative care with regard to medical and non-medical
indications, decision-making and ethical implications. It
is widely agreed, even though this is controversial too,
that in patients with advanced cancer and other terminal
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diseases the provision of sedation leading to unconscious-
ness sometimes can be a necessary therapeutic procedure
of last resort for symptom relief [1]. In the final stages of
life, symptoms may remain refractory. However, there is
much debate about where to draw the borderline between
sedation for refractory symptoms that are of a mainly
physical/somatic nature and for those psychological
symptoms that are mainly due to existential suffering.
Also, some think that sedation leading to unconscious-
ness should be an option, or an alternative, for terminally
ill patients with intolerable suffering if they request eutha-
nasia or physician assisted suicide [2–4] or for those who
just want "to die in sleep".
The problems associated with sedation in end-of-life care
and the different attitudes among clinicians and palliative
care experts are reflected in inconsistent terminology [5],
variation in techniques used to induce, maintain and
monitor sedation [6], duration of and frequency of appli-
cation, different concepts on the time of administering
sedation and on intentions [7]. While the ambiguous
term "terminal sedation (TS)" [8,9] is used most often,
other terms more clearly reflect the different viewpoints:
"sedation for intractable distress in the imminently dying
[10,11];", end-of-life sedation [12] "slow-euthanasia"
[13], "palliative sedation" [14], "total sedation" [15],
"sedation in the final phase", "palliative sedation therapy"
[16].
Sedation in the terminal or final stages of life can be
defined as the use of sedative drugs (usually benzodi-
azepines with or without complementary opioids given
by the intravenous or by the subcutaneous route) to
reduce the level of consciousness sufficiently deep to pro-
vide comfort for the patient until death occurs. According
to the EAPC Ethics Task Force "terminal' or 'palliative'
sedation in those imminently dying must be distin-
guished from euthanasia. In terminal sedation the inten-
tion is to relieve intolerable suffering, the procedure is to
use a sedating drug for symptom control, and the success-
ful outcome is the alleviation of distress. In euthanasia the
intention is to kill the patient, the procedure is to administer
a lethal drug and the successful outcome  is immediate
death. In palliative care mild sedation may be used thera-
peutically but in this situation it does not adversely affect
the patient's conscious level or ability to communicate
[17]. The use of heavy sedation (which leads to uncon-
sciousness) may sometimes be necessary to achieve iden-
tified therapeutic goals. The intention is the relief of
otherwise intractable and refractory distress [18]. Target
symptoms include persisting pain, delirium, dyspnoea,
nausea and vomiting, massive haemorrhage, agitated anx-
iety and other forms of psychological distress. Sedation
can be classified into mild to deep, intermittent to contin-
uous, primary to secondary, sudden to slow [19]. Contro-
versies exist about the time limit and proximity to death
[20], the clinical implications (e.g. the withdrawal of
nutrition and hydration [21,22]), patient monitoring, the
stage and circumstances of the illness in which sedation
can be offered or employed, and the informed consent
process with patients and surrogates [23]. Requests for
sedation seem to become of increasing relevance in
advance directives, but the ethical implications may rise to
conflicts between patients' wishes to hasten death and
physicians' intentions to provide the best care and not to
shorten life.
In particular, there is controversy on the issues of dehydra-
tion in sedation for existential suffering [24]. The increas-
ing acceptance and use of "terminal sedation" [25] in end-
of-life care makes it necessary to scrutinize guidelines,
which may help to continuously consider and reconsider
the needs and wishes of patients and surrogates, as well as
intentions and concerns of caregivers.
The use of sedation in terminally ill patients has been
investigated by a number of studies in recent years. The
wide variations in frequency to choose sedation as an pro-
cedure in end-of-life care across different centres suggest
different attitudes of doctors and policies of institutions
rather than the patients' preferences or needs [26]. The
purpose of this retrospective study was to investigate rea-
sons for the request and the application of sedation in ter-
minal situations in our palliative care unit in the years
1995–2002, and the relevance of guidelines.
Methods
We performed a systematic retrospective analysis of the
charts of all patients who received continuous or intermit-
tent sedation by the administration of benzodiazepines
intravenously within the last 48 hrs before death in the
Palliative Care Unit (PCU) of GK Havelhöhe between
1995 and 2002. During this period there was no change
in the medical staff of the unit. Indications, decision-mak-
ing and techniques were regulated according to internal
guidelines, which were introduced after discussion with
the medical and nursing staff at the beginning of the
observation period (Table 1). Indication and beginning of
sedation was documented in the medical records.
The medical charts of all patients (n= 548), who died dur-
ing the observation period where investigated in order to
find out those, who had sedation in the final stage of their
life. A ranking of symptoms on admission, during treat-
ment and in the last 48 hrs was made according to our
symptom assessment scale with the items: pain, gastroin-
testinal (nausea/emesis/intestinal obstruction), dysp-
noea, anxiety/depression, fatigue/cachexia, cognitive
disorder/delirium (drowsiness/agitation), bleeding, skin
problems (ulcerations, oedema), neurological and others.BMC Palliative Care 2003, 2 http://www.biomedcentral.com/1472-684X/2/2
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Data collection, rating and analysis was made by a single
member of the medical staff. Reduction of rating and
ranking errors in doubtful cases was achieved by comple-
mentary interviews with those involved more personally
in the medical care of the patients. In this study the single
rater method (by the clinically most experienced physi-
cian) was preferred to reduce disagreement on symptom
definitions in trust on the experience and accuracy of an
individual point of view though recollection of data
sometimes was difficult to obtain. Charts of patients with
sedation were reviewed and evaluated systematically and
discussed with those involved in the decision-making on
sedation in the terminal or final phase. A ranking was
made to identify a single predominant symptom, which
mainly lead to sedation and concomitant others. 6 pre-
dominant symptoms for sedation were differentiated:
dyspnoea, pain, delirium/agitation, gastrointestinal,
bleeding, anxiety/psychological distress. The recorded
indications for sedation were classified into "mainly phys-
ical" when refractory physical symptoms predominated
and "mainly psychological", when intolerable suffering
by panic anxiety, refractory insomnia or affective decom-
pensation persisted. Agitated delirium was separated due
to the diagnostic uncertainty to relate this symptom to a
more physical or more psychological origin retrospec-
tively. Attention was given to the stage of disease at the
time of admission, prevalence of symptoms on admission
and in the final phase, changes of symptoms during treat-
ment, type and duration of sedation until death, survival
time after administration of the sedatives, provision of
concomitant therapy, nutrition supply and fluids, state of
consciousness and communication skills. Special interest
was given to patients' attitudes and frequency of request
for sedation in the final phase as documented in the med-
ical records or in advance directives. Patients' characteris-
tics were related to all patients admitted.
The data were analysed using SPSS Version 11. Chi-
squared tests were used to examine associations between
categorical data. Metric data (age, duration of stay, dura-
tion of sedation) were compared using Student's t-test for
independent groups. Comparisons between groups for
predominant symptoms were made using the Mann-
Whitney U-test and Wilcoxon rank-sum test for paired
comparison within patients' groups. P < .05 was consid-
ered statistically significant. On the base of these data a
critical evaluation for the decisions on sedation was made
comparing the periods between 1995–1999 and 2000–
2002.
Results
- Patients' characteristics showed no significant difference
in the stage of disease on admission (Table 2). But
patients who finally received sedation were more likely to
have experienced pain, dyspnoea and anxiety as the pre-
dominant symptom on admission than those who did
not undergo sedation (Table 4).
- Sedation in the last 48 hrs was performed in 14,6 % (n =
80) of all patients who died in the PCU of GK Havelhoehe
(n = 548) with significantly increasing frequency in the
years 2000–2002 (χ2 = 8.57; p = 0.003) (Figure 1).
- No difference was found in the duration of stay in our
unit until death between those patients who died with,
and those who died without sedation. Mean age of
patients, who finally had sedation was less with 54 years
vs. 64 years in those without sedation (p = 0.001, Stu-
dent's t-test).
- All patients had effective and sufficient pain control, but
in those patients who were sedated in the last 48 hrs of
life, burdensome dyspnoea, panic-stricken anxiety and
agitated delirium had increased during the stay (Figure 2).
- The indications for performing sedation due to predom-
inant psychological distress (anxiety, refractory insomnia,
decompensation) and due to refractory symptoms (dysp-
noea, gastrointestinal, pain) did not differ significantly
during the two observational periods. Interestingly, there
was a tendency that the main indications for sedation
during the last three years shifted more and more to psy-
chological distress.
- Mean survival time after administration of sedation was
63 ± 58 hrs during the whole observation period. In the
years 2000–2002 patients with more psychological dis-
tress had a longer survival time than those with otherwise
resistant control of more physical symptoms (Table 3).
- In the years 2000–2002 we noticed an increase in the
request for sedation in the final days of life from 19% to
Table 1: Guidelines for the use of sedation in patients near death 
in PCU Havelhoehe
Indication:
Otherwise refractory and burdensome symptoms In terminal or final 
stages of the life of patients with Incurable disease – If death can be 
expected within the next 48 hrs
Decision-making:
Informed consent of patient, surrogates and palliative care team
Technique:
Continuous or Intermittent innfusion of sedatives (iv or sc e.g. mida-
zolam 0,5 -mg/h +/- analgesics + co-medlcatlon). Lowest possible, ade-
quate dosage to control symptoms under permanent observation and 
careful monitoring. Reduction of dosage In agony. Maintenance of all 
necessary medical and nursing support. Documentation.
Intention and ethics:
Reduction of distress, good sleep at night, adequate communication at 
daytime. Comfort and tolerance In the final phase – not to hasten 
death.BMC Palliative Care 2003, 2 http://www.biomedcentral.com/1472-684X/2/2
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34% by the patients themselves, documented in personal
statements or advance directives. In those patients in
which sedation was given also "on request", the mean
survival time was found to be slightly shorter (52 ± 42 hrs)
in the years 2000–2002, but not in the years before (Table
3).
- In most cases, sedation was performed with slowly
increasing doses of midazolam 0,5 mg – 8 mg/h iv, aimed
at achieving effective symptom control. When this was
obtained, doses were reduced and sedation was continued
intermittently with the documentation of the level of con-
sciousness, comfort, eating, drinking and communication
skills. 48 patients had continuous sedation (mean dura-
tion 53 hrs), 32 intermittent (mean duration 77 hrs). In
53 patients (66%) oral supply of fluids and in 10 patients
also oral nutrition intake during sedation was reported in
the records. 27 patients (33.8%), had no oral fluid or
nutrition supply after sedation was introduced either
because of the deepness of the sedation or because of
refusal of oral fluid and nutrition intake. Infusion of fluids
was continued in all patients with regard on comfort
according to clinical signs of thirst with restriction of vol-
umes in cases of oedema, ascites and pulmonary conges-
tion. Special attention was given to establish a good
sleeping period at night and a more patient controlled
sedative state with communicative skills and reports of
comfort during the day.
- Abilities to communicate like asking for help or answer-
ing questions on pain, comfort, thirst etc. and preserved
forms of cooperation under sedation were reported in 40
cases (50%).
- The following case of a 40 yrs old hospice worker, in
whom oropharyngeal cancer was diagnosed during preg-
nancy, may illustrate the procedure of sedation in our
PCU but also the difficulties associated with drawing the
line in consideration of patients needs, personal inten-
tions and adequacy of sedative procedures for refractory
symptom control:
For several weeks she was treated for panic attacks, dyspnoea
and dysphagia but relief of symptoms only lasted a few days.
Her weakness increased rapidly. In her advance directives she
had disclaimed tracheotomy and antibiotics but pleaded for
Table 2: Patients characteristics on admission – demographic and clinical data of all patients in comparison to those who died in PCU 
Havelhoehe 1995–2002. Significant differences were found between groups on age and stages on admission except preterminal stage.
All admissions (A) Subgroup (B) Subgroup (C) Significance p-values
All patients (n = 1467) † without sed. (n = 468) † with sed. (n = 80)
Gender (%)
female 55.8 57.1 61.2 n.s.
Age (years)
Mean (SD) 60,8 (17.8) 63.6 (13.3)* 54.3 (14.4)** *p = 0.026
Range (19.7–97.7) (24.6–97.7) (19.7–81.1) **P < 0.001.
Stage on admission (%)
Rehabilitative 33.3 15.1** 13.8** **P < 0.001
Preterminal 44.3 42.2 43.8 P = 0.445
Terminal 19.6 36.6** 38.7** **P < 0.001
Final 2.8 6.2* 3.8* *P = 0.002
Duration of stay (days)
Mean (SD) 21.0 (21.5) 21.1 (23.6) 21.5 (20.3) n.s.
Median 16 14.0 15.5
Range (0 – 233) (0 – 199) (1 – 109)
Primary cancer site (%)
Gastrointestinal 21.6 24.4 27.2 n.s.
Breast 15.4 15.6 6.2 P = 0.06 n.s.
Lung, bronchus & trachea 12.8 14.9 16.0 n.s.
Prostate 8.8 5.2 3.7 n.s
Female genital 8.6 9.7 14.8 n.s.
Bones, skin & soft tissue 6.3 6.7 7.4 n.s.
Nervous system 3.8 3.7 1.2 n.s.
Urinary system 3.8 3.7 7.4 P = 0.085 n.s.
Oropharynx & hypopharynx 3.7 4.1 7.4 P = 0.085 n.s.
Lymphoma 3.5 4.3 3.7 n.s.
Others 1.2 2.1 4.9 n.s.
Non-cancer diagnosis 10.5 5.6** 0.0 P = 0.001BMC Palliative Care 2003, 2 http://www.biomedcentral.com/1472-684X/2/2
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good pain therapy and sedation "to die in sleep". In the final
phase she suffered from extensive mucositis, exhausting breath-
lessness and agitated anxiety by upper airway obstruction due to
local tumour progression, pulmonary and hepatic metastases
and acute pneumonia. She said: "I think – now the time has
come" and requested for sedation during the last hours of her
life. The clinical situation was discussed with the nursing team
according to our internal guidelines. Informed consent in pres-
ence of her husband was obtained before 5 mg iv midazolam
were administered with good symptom relief. Sedation was con-
tinued with a dosage of 1–2 mg/h on which the patient insisted
on comfort by the sedation and fear of recurring distress. Sur-
vival time was 16 hrs in a peaceful, quiet atmosphere without
distress, a light sedative state with diminished communication
skills, oral fluid intake and support by the presence of her
husband.
Discussion
To balance between therapeutic sedation to reduce bur-
densome distress in the terminal and dying phase and
sedation in patients who voluntary request sedation "to
die in sleep" is a difficult challenge. This is particularly
important when anxiety, physical distress and anxiety
with existential suffering appear together in the dying per-
son like in the illustrated case.
The intention of this survey is to contribute to the interna-
tional discussion on sedation in end-of-life situations. The
analysis was primarily done to reconsider our internal
guidelines by reflecting our clinical practice Certainly a
survey like this suffers from the drawbacks of a
retrospective study. Nevertheless our results can be under-
stood as a contribution to more transparency in this diffi-
cult issue. The increasing incidence and also the finding
that sedation was more often used in situations with
psychological distress and also requested by the patients'
themselves may indicate an increasing awareness and
respect for the needs of the patients. It also seems to sig-
nify that in the care of patients with physical symptoms
and psychological distress in situations near death needs
and deficits exist, for which sensitive medical strategies
must be combined and integrated with personal support,
commitment and understanding. In our guidelines we
tried to relate the possible benefits of sedation to the basic
concerns of palliative care by using it as a reversible ther-
apeutic procedure. Concentrating on communicated com-
fort as the main indicator for the value of this option
means also, that in the care of the sedated patients per-
sonal support played an important role.
Our decisions for the administration of sedation were
restricted to terminal and final situations when the course
of the disease had so progressed that death due to the
underlying disease could be expected within the next 48
hrs with or without this procedure. Nevertheless mean
survival time after administration of sedation was 63 hrs.
It is, in general, difficult to predict death in a particular
patient because of individual variations and since "we do
not know the exact borderline between life and death"
[27]. To a certain extent the point in time to accept dying
– at least in medical institutions – depends on empirically
based decisions to abstain from potentially life-sustaining
interventions e.g. pharmacological, technical or other arti-
ficial support of organ function "to prevent death" at least
for limited moments of time [28,29]. In our internal
guidelines we grouped patients according to the staging
Figure 1
Percentage of patients with sedation in the last 48 hrs in rela-
tion to the number of annual deaths (bars) in care of PCU 
Havelhoehe between 1995 and 2002. Significant increase of 
incidence for sedation in the period 2000–2002 (p = 0.015 in 
paired t-test)
Figure 2
Course of pain, dyspnoea, cognitive disorder (delirium) and 
psychological distress (anxiety) in patients with regard to 
application of sedation in the final phase (A= Subgroup with-
out sedation, B= Subgroup with sedation). Significance level p 
< 0.05 in Wilcoxon rank sum test.
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system of Jonen-Thielemann into rehabilitative, pretermi-
nal, terminal and final phases [30]. With relation to inten-
tions of care, life expectancy according to the progress of
disease and empirical statistics, consideration on perhaps
burdensome diagnostic and therapeutic procedures and
communication strategies with patients and proxies a sys-
tematic staging of patients in palliative care on expected
outcome seems to be useful. The predominant classifica-
tion into the preterminal stage of most of our patients on
admission signifies also the diagnostic uncertainty and
difficulty with such a staging system with relationship to
responsible decision-making and consequences of care.
We considered sedation as a an palliative therapeutic
option of last resort in the last stages of life. Many experts
prefer the term "palliative sedation" instead of "terminal
sedation". Though the term "palliative sedation" seems to
be more appropriate, it must be distinguished from those
situations in other phases of palliative care, when pallia-
tive sedation is used for burdensome diagnostic or painful
therapeutic procedures (e.g. wound debridement and
dressing of exulcerating tumours, insertion of catheters)
and usually does not exceed the time in which the proce-
dure is undertaken. Among the most controversial dis-
cussed issues of "terminal sedation" are the questions of
when and for which forms of intractable suffering seda-
tion may be indicated. Another central point refers to the
question of how to distinguish clearly the crucial
intention of relief providing sedation from (slow) eutha-
nasia by the application of lethal doses of sedatives [31].
In our study we found that dyspnoea, delirium and anxi-
ety increased during the treatment period in those
patients who finally had sedation while pain was signifi-
cantly reduced by adequate treatment during the progress-
ing course of the disease (Figure 2). This finding is in
confirmation with other studies, in which besides acute
bleeding and gastrointestinal symptoms, distressing dysp-
noea, delirium and agitated anxiety also where found to
be the main reasons for sedation in end-of-life care [32].
The adequate treatment and care of patients of patients
with otherwise refractory symptoms certainly is a great
challenge in palliative care and improvement in this field
is needed urgently. Our target in sedation is calming and
comfort without lowering the level of consciousness deep
enough to loose communication. This also means, that
sedation cannot compensate personal palliative support
and care – it must be combined. Our study indicates also,
that psychosocial distress contributed to the decision
making, especially when patients had made an advance
directive with requests for sedation in the last phase of
life. In our study the shorter survival time after adminis-
tration of sedation in patients who had made an request
Table 3: Indication for sedation, patients' request and observational reports on communication and oral fluid/nutrition intake 
comparing the periods 1995–1999 and 2000–2002 (*p < 0.05).
Whole Period
1995 – 2002
Period 1995–1999 Period 2000 – 2002 Significance p-values
Patients with sedation in the last 48 hrs
n (% of all deaths) 80 (14.6) 31 (10.6) 49 (18.9)* **P = 0.007
Main indication for sedation, n (%)
Dyspnoea 28 (35.0) 11 (35.5) 17 (34.7) n.s.
Gastrointestinal 6 (7.5) 3 (9.7) 3 (6.1) n.s.
Bleeding 1 (1.3) 1 (3.2) 0 (0.0) n.s.
Pain 2 (2.5) 1 (3.2) 1 (2.0) n.s.
Delirium, agitation 11 (13.8) 6 (19.4) 5 (10.2) n.s.
Anxiety, psychological distress 32 (40.0) 9 (29.0) 23 (46.9) P = 0.111
Requests for sedation, n (%) 23 (28.8) 6 (19.4) 17 (34.4) P = 0.141
Duration of sedation (hrs)
Mean (SD) 62.8 (58.0) 69.0 (57.5) 58.9 (58.7) P = 0.445
Range 2–264 15 – 240 2 – 264
Mainly somatic indication 63.3 (56.3) 84.7 (64.0) 47.3 (45.1) P = 0.117
Mainly psychological indication 62.6 (60.3) 52.2 (46.0) 68.3 (67.1) P = 0.145
Patients with request for sedation 57.3 (47.3) 73.0 (53.0) 51.8 (45.2) P = 0.198
Type of sedation and clinical state:
Continuous, n (%) 48 (60.0) 15 (48.4) 33 (67.3) P = 0.092
Intermittent, n (%) 32 (40.0) 16 (51.6) 16 (32.7) P = 0.092
With communication, n (%) 42 (51.3) 16 (51.5) 26 (53.1) n.s.
With oral fluid intake, n (%) 53 (66.3) 15 (48.4) 38 (77.6)* P = 0.007
With oral nutrition, n (%) 10 (12.5) 5 (16.1) 5 (10.2) n.s.BMC Palliative Care 2003, 2 http://www.biomedcentral.com/1472-684X/2/2
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for sedation might be due to the fact that in those patients
the medical indications and preconditions were consid-
ered more intensively while the underlying disease
progressed.
The ethical dilemmas and the possibilities to abuse seda-
tion by turning it in a form of medicalised killing [33,34]
are important aspects that seem to restrict the administra-
tion of sedatives in terminally ill patients. In studies on
survival time of patients with and without sedation no sig-
nificant differences were found. [35–37]. Certainly also
the cultural background determines attitudes and view
points to the goals of care and in which situations of
"intolerable suffering" sedation is ethically acceptable
[38]. In several retrospective and prospective surveys the
reported frequency of sedation due to intractable symp-
toms in different palliative care settings ranged from 7–
52% with increasing incidence especially for "existential
suffering" [39–41]. Diagnostic criteria and clinical pre-
conditions for the consideration of sedation in patients
with far advanced disease have been described by several
authors [42–44], but aims, targets, types of sedation and
decision making remain conflicting issues.
In modern Western culture, the elements of a "good
death" include, besides freedom of pain, death at home
with the family members being around, amongst others
also the element of "awareness". However, the technical
possibilities of palliative care with concentration on qual-
ity of life also brought about a "diminished emphasis on
the good death" [45]. Consequently, the increasing
requests of patients "to die in sleep" by terminal sedation
could be an comprehensible alternative to euthanasia or
physician-assisted suicide and must be reflected in the dis-
cussion on the value of sedation in end-of-life care.
Though we could not make a clear differentiation between
primary (when patients want to be sedated approaching
the moment of death) and secondary sedation (when
sedation results as a "side-effect" in otherwise refractory
symptom control [46], it must be clear to all, that the
intention of sedation in the terminal and final phase is
not a concealed form of euthanasia [47]. Under ethical
aspects the requests for sedation to reduce consciousness
to a state of unawareness need an individual and balanced
approach, especially when the wish for sedation is not
connected with the intolerability of physical or
psychological distress This makes it necessary to discuss
the problem of "terminal sedation" like other forms of
therapeutic and existential support with patients and fam-
ily members at an early stage in palliative care. Sedation
should be restricted as a reversible therapeutic option to
otherwise refractory suffering by burdensome symptoms
in the terminal and final phase, which may, but should
not intentionally, hasten death. With regard to symptom
relief the level of sedation must not necessarily need
"deep sleep" or bring about unconsciousness. The recent
consensus guidelines for dying intensive care patients
released in Canada provide a clear, but certainly also
problematic, definition of terminal sedation which distin-
guishes between "real" terminal sedation for therapeutic
Table 4: Predominant and concomitant symptoms on admission to PCU Havelhoehe.
Symptom All admissions (A) Subgroup 
(B)
Subgroup (C) Significance
All (n = 1467) † without sed.
(n = 468)
† with sed. (n = 80) p-Values
Predominant Concomitant Predominant Concomitant Predominant Concomitant
Pain 29,1% 56,3% 27,1% 54,0% 37,5% 70,0% n.s.
Gastrointestinal 
(nausea, vomiting, 
constipation & bowel 
obstruction)
17,4% 71,3% 11,7%* 55,9% 8,8%* 67,5% *p = 0.014
Dyspnoea 14,6% 31,2% 15,5% 33,1% 22,5% 46,3% n.s.
Psychological distress 
(anxiety/depression)
2,4% 34,0% 1,7% 20,9% 5,0% 37,5% n.s.
Cachexia/fatigue 9,3% 56,3% 17,4%** 65,9% 12,5% 66,3% **p < 0.001
Cognitive disorder/
delirium (drowsiness/
agitation)
8,5% 29,1% 11,2% 29,1% 3,8% 13,7% n.s.
Bleeding 2,4% 3,2% 1,3% 3,8% 0,0% 1,3% n.s.
Skin (ulceration, 
oedema)
5,3% 42,5% 3,2% 31,4% 2,5% 35,0% n.s.
Neurological 8,9% 33,6% 8,7% 27,1% 6,3% 26,3% n.s.
Others 2,1% 34,2% 2,2% 22,0% 1,1% 14,5% n.s.BMC Palliative Care 2003, 2 http://www.biomedcentral.com/1472-684X/2/2
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intentions and terminal sedation as a possible form of
euthanasia by lethal doses of sedatives. The Canadian
guidelines define "Terminal Sedation" as "sedation with
continuous IV narcotics and/or sedatives until the patient
becomes unconscious and death ensues from the underly-
ing illness". Emphasis is added that the balance between
possible euthanasia and inadequate palliative care is
achieved by titrating the dosage of sedatives so that one
avoids over- or under medication to allow death to result
from the underlying disease in a state of continuing
unconsciousness [48].
According to our guidelines after the intended provision
of relief and symptom alleviation initially our approach
in most cases was to reach a state of "conscious sedation"
by reducing the dosages of sedatives to a level of commu-
nication that revalidation of the clinical situation could be
achieved. This form of a patient controlled sedative state
was explained to the patients and family members before
induction of sedation – especially to those who had a
request for sedation in their advance directives. No objec-
tion to this procedure was mentioned except in one case,
where a female patient requested for sedation after an
emergency operation for intestinal obstruction in case
that it would not bring the expected result. The intention
on comfort in the terminal and final phase should be the
main concern in finding ethically acceptable criteria for
the use of sedation in end-of-life care and to avoid misuse
of terminal sedation.
Conclusions
The results of our study indicate that sedation in end-of-
life care seems to become an increasing ethical problem
with attention to patients' wishes and needs and physi-
cians' integrity. This is not only a problem for those
involved in palliative and hospice care. "Since terminal
sedation may arguably make the detection of euthanasia/
assisted suicide more difficult... the intent of the physician
is the most crucial distinction" [45]. But beside intention,
the adequacy of what is done must also be taken into
account. The concentration on comfort and symptom
alleviation by titrating the sedative medication to a level
that allows assessment and communication are important
aspects which should be considered in the ongoing
discussion on sedation in the last stages of life. Ethically
acceptable criteria and guidelines for decision making
with regard to the nature of refractory and intolerable
symptoms, patients' needs, aims of sedation and
informed consent are needed [49]. Based on these, pro-
spective clinical studies with systematic documentation of
cases, transparency and critical communication with
regard to indications, intentions, procedures, alternatives,
results and adverse effects would help to locate the appro-
priate place of sedation in end-of-life care and diminish
misuse or moral prejudices.
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